Observational studyStem cells translational medicine2026
Factors affecting outcomes of intra-articular injection of autologous, culture-expanded, adipose-derived mesenchymal stem cells in knee osteoarthritis.
Observational study in Stem cells translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04427930 (Long-Term Safety and Efficacy Extension Study Of Autologous Adipose-Derived Mesenchymal Stem Cells 『JOINTSTEM』 in Patients With Knee Osteoarthiritis), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Long-Term Safety and Efficacy Extension Study Of Autologous Adipose-Derived Mesenchymal Stem Cells 『JOINTSTEM』 in Patients With Knee Osteoarthiritis: A Phase III Extension Study
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThis study aims to assess the outcomes of intra-articular injection of adipose-derived mesenchymal stem cells (ADMSC) in osteoarthritis (OA) of knee joint up to 3-year follow-up and evaluate possible factors related to the outcomes.
methodsThis was a prospective observational follow-up of participants from the ADMSC treatment arm of a prior phase III clinical trial. A total of 104 patients were assessed through the follow-up study for 3 years after ADMSC injection. We assessed the WOMAC and VAS for pain at 1-, 2-, and 3-year post-injection and compared with baseline values. Minimal clinically important difference (MCID) was calculated, and the proportion of patients achieving MCID was evaluated at each time point. Finally, we assessed which factors may affect the outcome.
resultsSignificant improvements in WOMAC and VAS scores were observed after ADMSC injection, with these benefits sustained throughout the 1-, 2-, and 3-year follow-up. The proportion achieving MCID slightly decreased over time without statistical significance. Significant factors affecting the favorable outcomes were lower body mass index (BMI) (<25), higher baseline clinical scores up to 3 years after the injection. Other variables did not show the significant relation.
conclusionsIntra-articular injection of autologous, culture-expanded ADMSC in patient with knee OA was sustained improvements observed up to 3 years in terms of WOMAC and VAS values. Moreover, patient BMI and baseline WOMAC were related to the outcomes after a single injection. Patient condition including severity of pain may affect the effect of ADMSC injection in OA knee. Clinical trial registration number: NCT04427930. This study was retrospectively registered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.